Plaque deposition dependent decrease in 5-HT2A serotonin receptor in AbetaPPswe/PS1dE9 amyloid overexpressing mice

Peter Holm1, Anders Ettrup, Anders B Klein

  • 1Neurobiology Research Unit and Center for Integrated Molecular Brain Imaging, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.

Insights

Alzheimer's disease models show amyloid-beta plaque buildup reduces 5-HT2A receptor levels and function. This change is linked to amyloid accumulation, not serotonin transporter levels.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Alzheimer's Disease Research

Background:

  • Amyloid-beta (Abeta) accumulation is central to Alzheimer's disease pathology.
  • Reduced hippocampal 5-HT2A receptor levels are observed in Abeta-induced memory impairment.

Purpose of the Study:

  • To investigate the relationship between progressive Abeta accumulation and 5-HT2A receptor regulation and function.
  • To examine age-dependent changes in 5-HT2A receptor binding and functionality in a mouse model of Alzheimer's disease.

Main Methods:

  • Utilized AbetaPPswe/PS1dE9 double transgenic mice across three age groups (4, 8, and 11 months).
  • Performed autoradiography for 5-HT2A receptors, SERT, and Abeta plaques ([11C]-PIB).
  • Assessed 5-HT2A receptor functionality via DOI-induced head-twitch response (HTR) and c-fos mRNA expression.

Main Results:

  • Abeta plaque burden increased with age, correlating with decreased 5-HT2A receptor binding in the medial prefrontal cortex (mPFC).
  • 5-HT2A receptor binding changes were negatively correlated with [11C]-PIB binding and independent of SERT levels.
  • Diminished DOI-induced HTR and reduced c-fos mRNA induction were observed in older transgenic mice.

Conclusions:

  • Abeta accumulation is directly associated with reduced 5-HT2A receptor expression and function.
  • These changes occur independently of alterations in the upstream serotonergic system.
  • Findings suggest a specific link between Abeta pathology and 5-HT2A receptor dysregulation in Alzheimer's disease progression.

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...